Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced-stage classical Hodgkin lymphoma (stage III to IV), drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Long-term outcomes of nivolumab-AVD beyond a few years are not yet known.
Nivolumab-AVD and BrECADD have never been compared.
Older patients still have worse survival and more toxicity.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Whether chemotherapy can be reduced further with PD-1 antibodies is the next trial question.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
4-year PFS 94.
A milestone in how this cancer is treated.
2-year PFS 92% vs 83%, HR 0.
Three-year event-free survival 92.
A milestone in how this cancer is treated.